Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Robert Bishop

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Concepts & Ideas

Structure-Activity Relationship

Genes & Molecular Sequences

ras Genes

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
30
Kirschmeier, Paul
14
Liu, Ming
14
Doll, Ronald
12
Girijavallabhan, Viyyoor
12
Njoroge, George
10
Vibulbhan, Bancha
10
Wang, Luquan
10
James, Linda
9
Ganguly, Ashit
9
Petrin, J
8
Nomeir, Amin
8
Bryant, Matthew
8
Catino, JJ
7
Patton, Robert
6
Pinto, Patrick

Sign-in to see all Coauthors

Publications

TOP 3
Liu Gongjie; Taylor Stacey A; Marrinan Cindy H; Hsieh Yunsheng; Bishop W Robert; Kirschmeier Paul; Long Brian J
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Taylor Stacey A; Marrinan Cindy H; Liu Gongjie; Nale Lissette; Bishop W Robert; Kirschmeier Paul; Liu Ming; Long Brian J
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Njoroge F George; Vibulbhan Bancha; Pinto Patrick; Strickland Corey; Bishop W Robert; Nomeir Amin; Girijavallabhan Vivyoor
Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Robert Bishop (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Liu Gongjie; Taylor Stacey A; Marrinan Cindy H; Hsieh Yunsheng; Bishop W Robert; Kirschmeier Paul; Long Brian J
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
International journal of cancer. Journal international du cancer 2009;125(11):2711-20.
2008: Taylor Stacey A; Marrinan Cindy H; Liu Gongjie; Nale Lissette; Bishop W Robert; Kirschmeier Paul; Liu Ming; Long Brian J
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Gynecologic oncology 2008;109(1):97-106.
2006: Njoroge F George; Vibulbhan Bancha; Pinto Patrick; Strickland Corey; Bishop W Robert; Nomeir Amin; Girijavallabhan Vivyoor
Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.
Bioorganic & medicinal chemistry letters 2006;16(4):984-8.
2006: Basso Andrea D; Kirschmeier Paul; Bishop W Robert
Lipid posttranslational modifications. Farnesyl transferase inhibitors.
Journal of lipid research 2006;47(1):15-31.
2005: Basso Andrea D; Mirza Asra; Liu Gongjie; Long Brian J; Bishop W Robert; Kirschmeier Paul
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
The Journal of biological chemistry 2005;280(35):31101-8.
2005: Wang Yan; Hailey Judith; Williams Denise; Wang Yaolin; Lipari Philip; Malkowski Michael; Wang Xiaoying; Xie Lei; Li Guanghua; Saha Deba; Ling Wai Lam W; Cannon-Carlson Susan; Greenberg Robert; Ramos Robert A; Shields Robert; Presta Leonard; Brams Peter; Bishop W Robert; Pachter Jonathan A
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.
Molecular cancer therapeutics 2005;4(8):1214-21.
2005: Wu Qun; Ding Wei; Mirza Asra; Van Arsdale Tish; Wei Iris; Bishop W Robert; Basso Andrea; McClanahan Terri; Luo Lin; Kirschmeier Paul; Gustafson Eric; Hernandez Marco; Liu Suxing
Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target.
The Journal of biological chemistry 2005;280(13):12935-43.
2004: Njoroge F George; Vibulbhan Bancha; Pinto Patrick; Strickland Corey; Kirschmeier Paul; Bishop W Robert; Girijavallabhan V
Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.
Bioorganic & medicinal chemistry letters 2004;14(23):5877-80.
2004: Doll Ronald J; Kirschmeier Paul; Bishop W Robert
Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Current opinion in drug discovery & development 2004;7(4):478-86.
2004: Khuri Fadlo R; Glisson Bonnie S; Kim Edward S; Statkevich Paul; Thall Peter F; Meyers Michael L; Herbst Roy S; Munden Reginald F; Tendler Craig; Zhu Yali; Bangert Sandra; Thompson Elizabeth; Lu Charles; Wang Xue-Mei; Shin Dong M; Kies Merrill S; Papadimitrakopoulou Vali; Fossella Frank V; Kirschmeier Paul; Bishop W Robert; Hong Waun Ki
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2968-76.
2003: Liu Suxing; Bishop W Robert; Liu Ming
Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(4):183-95.
2003: Bishop W Robert; Kirschmeier Paul; Baum Charles
Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation.
Cancer biology & therapy 2003;2(4 Suppl 1):S96-104.
2003: Mirza Asra; Wu Qun; Wang Luquan; McClanahan Terri; Bishop W Robert; Gheyas Ferdous; Ding Wei; Hutchins Beth; Hockenberry Tish; Kirschmeier Paul; Greene Jonathan R; Liu Suxing
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.
Oncogene 2003;22(23):3645-54.
2003: Njoroge F George; Vibulbhan Bancha; Pinto Patrick; Strickland Corey L; Bishop W Robert; Kirschmeir Paul; Girijavallabhan V; Ganguly Ashit K
Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.
Bioorganic & medicinal chemistry 2003;11(1):139-43.
2002: Hailey Judith; Maxwell Eugene; Koukouras Kathy; Bishop W Robert; Pachter Jonathan A; Wang Yan
Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells.
Molecular cancer therapeutics 2002;1(14):1349-53.
2002: Mirza Asra; McGuirk Marnie; Hockenberry Tish N; Wu Qun; Ashar Hena; Black Stuart; Wen Shu Fen; Wang Luquan; Kirschmeier Paul; Bishop W Robert; Nielsen Loretta L; Pickett Cecil B; Liu Suxing
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
Oncogene 2002;21(17):2613-22.
2002: Cooper Alan B; Strickland Corey L; Wang James; Desai Jagdish; Kirschmeier Paul; Patton Robert; Bishop W Robert; Weber Patricia C; Girijavallabhan V
Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.
Bioorganic & medicinal chemistry letters 2002;12(4):601-5.
2002: Brassard Diana L; English Jessie M; Malkowski Michael; Kirschmeier Paul; Nagabhushan T L; Bishop W Robert
Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Experimental cell research 2002;273(2):138-46.
2001: Peters D G; Hoover R R; Gerlach M J; Koh E Y; Zhang H; Choe K; Kirschmeier P; Bishop W R; Daley G Q
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Blood 2001;97(5):1404-12.
2001: Ashar H R; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll R J; Taveras A G; Bishop W R; Kirschmeier P
The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Experimental cell research 2001;262(1):17-27.
2001: Liu M; Bishop W R; Nielsen L L; Bryant M S; Kirschmeier P
Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models.
Methods in enzymology 2001;333():306-18.
2001: Kirschmeier P T; Whyte D; Wilson O; Bishop W R; Pai J K
In vivo prenylation analysis of Ras and Rho proteins.
Methods in enzymology 2001;332():115-27.
2000: Ashar H R; Armstrong L; James L J; Carr D M; Gray K; Taveras A; Doll R J; Bishop W R; Kirschmeier P T
Biological effects and mechanism of action of farnesyl transferase inhibitors.
Chemical research in toxicology 2000;13(10):949-52.
2000: Ashar H R; James L; Gray K; Carr D; Black S; Armstrong L; Bishop W R; Kirschmeier P
Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.
The Journal of biological chemistry 2000;275(39):30451-7.
2000: Adjei A A; Erlichman C; Davis J N; Cutler D L; Sloan J A; Marks R S; Hanson L J; Svingen P A; Atherton P; Bishop W R; Kirschmeier P; Kaufmann S H
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Cancer research 2000;60(7):1871-7.
2000: Trempus C S; Bishop W R; Njoroge F G; Doll R J; Battalora M S; Mahler J F; Haseman J K; Tennant R W
A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse.
Molecular carcinogenesis 2000;27(1):24-33.
2000: Shi B; Yaremko B; Hajian G; Terracina G; Bishop W R; Liu M; Nielsen L L
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Cancer chemotherapy and pharmacology 2000;46(5):387-93.
1999: Nielsen L L; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop W R; Liu M
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Cancer research 1999;59(23):5896-901.
1999: Afonso A; Weinstein J; Kelly J; Wolin R; Rosenblum S B; Connolly M; Guzi T; James L; Carr D; Patton R; Bishop W R; Kirshmeier P; Liu M; Heimark L; Chen K J; Nomeir A A
Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.
Bioorganic & medicinal chemistry 1999;7(9):1845-55.
1999: Taveras A G; Deskus J; Chao J; Vaccaro C J; Njoroge F G; Vibulbhan B; Pinto P; Remiszewski S; del Rosario J; Doll R J; Alvarez C; Lalwani T; Mallams A K; Rossman R R; Afonso A; Girijavallabhan V M; Ganguly A K; Pramanik B; Heimark L; Bishop W R; Wang L; Kirschmeier P; James L; Carr D; Liu M
Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.
Journal of medicinal chemistry 1999;42(14):2651-61.
1999: Afonso A; Kelly J; Weinstein J; James L; Bishop W R
Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclo hepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase.
Bioorganic & medicinal chemistry letters 1999;9(13):1875-80.
1999: Njoroge F G; Vibulbhan B; Bishop W R; Kirschmeier P; Bryant M S; Nomeir A A; Liu M; Doll R J; Girijavallabhan V M; Ganguly A K
Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity.
Bioorganic & medicinal chemistry 1999;7(5):861-7.
1999: Liu M; Bryant M S; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman R R; Korfmacher W A; Nomeir A A; Lin C C; Mallams A K; Doll R J; Catino J J; Girijavallabhan V M; Kirschmeier P; Bishop W R
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Cancer chemotherapy and pharmacology 1999;43(1):50-8.
1998: Njoroge F G; Taveras A G; Kelly J; Remiszewski S; Mallams A K; Wolin R; Afonso A; Cooper A B; Rane D F; Liu Y T; Wong J; Vibulbhan B; Pinto P; Deskus J; Alvarez C S; del Rosario J; Connolly M; Wang J; Desai J; Rossman R R; Bishop W R; Patton R; Wang L; Kirschmeier P; Ganguly A K
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
Journal of medicinal chemistry 1998;41(24):4890-902.
1998: Liu M; Bryant M S; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher W A; Nomeir A A; Lin C C; Wang L; Taveras A G; Doll R J; Njoroge F G; Mallams A K; Remiszewski S; Catino J J; Girijavallabhan V M; Bishop W R
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Cancer research 1998;58(21):4947-56.
1998: Wolin R; Connolly M; Kelly J; Weinstein J; Rosenblum S; Afonso A; James L; Kirschmeier P; Bishop W R
Inhibitors of farnesyl protein transferase. Synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system.
Bioorganic & medicinal chemistry letters 1998;8(18):2521-6.
1998: Kelly J; Wolin R; Connolly M; Afonso A; James L; Kirshmeier P; Bishop W R; McPhail A T
Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo[5,6]cyclohepta[1,2-b]pyridines: sulfonamido derivatives as inhibitors of Ras prenylation.
Bioorganic & medicinal chemistry 1998;6(6):673-86.
1998: Njoroge F G; Vibulbhan B; Pinto P; Bishop W R; Bryant M S; Nomeir A A; Lin C; Liu M; Doll R J; Girijavallabhan V; Ganguly A K
Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity.
Journal of medicinal chemistry 1998;41(10):1561-7.
1998: Mallams A K; Rossman R R; Doll R J; Girijavallabhan V M; Ganguly A K; Petrin J; Wang L; Patton R; Bishop W R; Carr D M; Kirschmeier P; Catino J J; Bryant M S; Chen K J; Korfmacher W A; Nardo C; Wang S; Nomeir A A; Lin C C; Li Z; Chen J; Lee S; Dell J; Lipari P; Liu M
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.
Journal of medicinal chemistry 1998;41(6):877-93.
1997: Njoroge F G; Vibulbhan B; Rane D F; Bishop W R; Petrin J; Patton R; Bryant M S; Chen K J; Nomeir A A; Lin C C; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll R J; Girijavallabhan V; Ganguly A K
Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
Journal of medicinal chemistry 1997;40(26):4290-301.
1997: Whyte D B; Kirschmeier P; Hockenberry T N; Nunez-Oliva I; James L; Catino J J; Bishop W R; Pai J K
K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.
The Journal of biological chemistry 1997;272(22):14459-64.
1997: Zhang F L; Kirschmeier P; Carr D; James L; Bond R W; Wang L; Patton R; Windsor W T; Syto R; Zhang R; Bishop W R
Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I.
The Journal of biological chemistry 1997;272(15):10232-9.
1997: Njoroge F G; Doll R J; Vibulbhan B; Alvarez C S; Bishop W R; Petrin J; Kirschmeier P; Carruthers N I; Wong J K; Albanese M M; Piwinski J J; Catino J; Girijavallabhan V; Ganguly A K
Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.
Bioorganic & medicinal chemistry 1997;5(1):101-13.
1997: Mallams A K; Njoroge F G; Doll R J; Snow M E; Kaminski J J; Rossman R R; Vibulbhan B; Bishop W R; Kirschmeier P; Liu M; Bryant M S; Alvarez C; Carr D; James L; King I; Li Z; Lin C C; Nardo C; Petrin J; Remiszewski S W; Taveras A G; Wang S; Wong J; Catino J; Ganguly A K
Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.
Bioorganic & medicinal chemistry 1997;5(1):93-9.
1996: Zhang F L; Fu H W; Casey P J; Bishop W R
Substitution of cadmium for zinc in farnesyl:protein transferase alters its substrate specificity.
Biochemistry 1996;35(25):8166-71.
1995: Bishop W R; Bond R; Petrin J; Wang L; Patton R; Doll R; Njoroge G; Catino J; Schwartz J; Windsor W
Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.
The Journal of biological chemistry 1995;270(51):30611-8.
1994: Zhang J; Wang L; Schwartz J; Bond R W; Bishop W R
Phosphorylation of Thr642 is an early event in the processing of newly synthesized protein kinase C beta 1 and is essential for its activation.
The Journal of biological chemistry 1994;269(30):19578-84.
1993: Zhang J; Wang L; Petrin J; Bishop W R; Bond R W
Characterization of site-specific mutants altered at protein kinase C beta 1 isozyme autophosphorylation sites.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(13):6130-4.
1992: Pachter J A; Pai J K; Mayer-Ezell R; Petrin J M; Dobek E; Bishop W R
Differential regulation of phosphoinositide and phosphatidylcholine hydrolysis by protein kinase C-beta 1 overexpression. Effects on stimulation by alpha-thrombin, guanosine 5'-O-(thiotriphosphate), and calcium.
The Journal of biological chemistry 1992;267(14):9826-30.
1992: Bishop W R; Pachter J A; Pai J K
Regulation of phospholipid hydrolysis and second messenger formation by protein kinase C.
Advances in enzyme regulation 1992;32():177-92.
1991: Pai J K; Dobek E A; Bishop W R
Endothelin-1 activates phospholipase D and thymidine incorporation in fibroblasts overexpressing protein kinase C beta 1.
Cell regulation 1991;2(11):897-903.
1991: Pai J K; Pachter J A; Weinstein I B; Bishop W R
Overexpression of protein kinase C beta 1 enhances phospholipase D activity and diacylglycerol formation in phorbol ester-stimulated rat fibroblasts.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(2):598-602.
1990: Bishop W R; Petrin J; Wang L; Ramesh U; Doll R J
Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin.
Biochemical pharmacology 1990;40(9):2129-35.
1990: Bishop W R; August J; Petrin J M; Pai J K
Regulation of sn-1,2-diacylglycerol second-messenger formation in thrombin-stimulated human platelets. Potentiation by protein kinase C inhibitors.
The Biochemical journal 1990;269(2):465-73.
1988: Bishop W R; Bell R M
Assembly of phospholipids into cellular membranes: biosynthesis, transmembrane movement and intracellular translocation.
Annual review of cell biology 1988;4():579-610.

Sign-in to see more